Učitavanje...
Adaptive resistance to RAF inhibitors in melanoma
The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma opened the door to new treatment options, which have resulted in significantly better patient outcomes. Treatments such as the FDA-approved RAF inhibitor vemurafenib, and the more recently approved dabrafenib and t...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4212018/ https://ncbi.nlm.nih.gov/pubmed/24828387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12264 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|